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OBJECTIVES: A once-weekly formulation of exenatide (EQW) received positive
opinion from the EMA in April 2011 for the treatment of type 2 diabetes. No head-
to-head study of EQW and liraglutide 1.2mg once-daily (the dose recommended by
NICE) has been conducted therefore a network meta-analysis to compare EQW to
liraglutide 1.2mg in terms of effect on HbA1c was performed.METHODS:A system-
atic review was conducted to identify randomized controlled trials of EQW and
liraglutide (1.2mg and 1.8mg) of 24 weeks or more, and the common comparators
insulin glargine and exenatide bid to allow a network meta-analysis. Additionally,
the manufacturing companies were asked to provide any unpublished data from
studies meeting the criteria. 22 studies including 10,816 patients met our inclusion
criteria. Treatments were compared in terms of mean difference in HbA1c relative
to placebo. Additionally, EQW was compared to both doses of liraglutide, and lira-
glutide 1.2mg was compared to liraglutide 1.8mg. RESULTS: Results from random
effects models controlling for baseline HbA1c are presented. Analysis of change in
HbA1c produced estimated mean differences relative to placebo of -1.15% (95% CI
-1.31, -1.00) for EQW, -1.01% (95% CI -1.18, -0.85) for liraglutide 1.2mg, and -1.18%
(95% CI -1.32%, -1.04%) for liraglutide 1.8mg. The comparison of EQW to liraglutide
1.2mg and liraglutide 1.8mg showed a mean difference (95% CI) of -0.14% (-0.34,
0.06) and 0.03% (-0.14, 0.18) respectively. Liraglutide 1.2mg compared to liraglutide
1.8mg showed a mean difference in HbA1c of 0.17% (0.02, 0.30). Results were con-
sistent when controlling for use of background antihyperglyemic medications.
CONCLUSIONS: Our analysis suggests EQW and both doses of liraglutide have
robust and similar efficacy with respect to lowering of HbA1c. Further analysis is
warranted to investigate the inconsistency between the direct and indirect evi-
dence with respect to the comparison of EQW to liraglutide 1.8mg.
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WEIGHT LOSS, INDEPENDENT OF DRUG CLASS, PREDICTS HBA1C GOAL
ATTAINMENT IN PATIENTS 65 YEARS AND OLDER IN A REAL-WORLD SETTING
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OBJECTIVES: To evaluate weight change and glycemic control in patients age 65
with type 2 diabetes (T2DM) in a usual-care setting. METHODS: Treatment naïve
patients age 65 years with T2DM and a prescription (index date) for a sulfonylurea
(SU), metformin (MET), thiazolidinedione (TZD), GLP-1 agonist (GLP-1), or DPP-4
inhibitor (DPP-4) were identified in an electronic medical record database from
1/1/2000 to 6/30/2010. HbA1c 7% or 7% and weight gain or loss of 3% were
assessed 1 year post-index. Logistic regression identified the likelihood of weight
loss and attaining HbA1c goal by antidiabetic drug class, controlling for baseline
HbA1c and weight, and for weight change for HbA1c goal attainment. RESULTS: Of
12,473 patients, 46.4% were male and the mean age was 71.7 (3.9) years. At base-
line 26.7% had HbA1c7.0%; mean weight 86.8 (18.7) kg. Breakdown by drug class
was: SU - 31.0%, MET - 55.0%, TZD - 11.6%, DPP-4 - 1.9%, and GLP-1 - 0.6%. At 1 year,
34.8% lost3% of body weight and 46.5% had an HbA1c7.0%. In logistic regression
analyses, MET and DPP-4 (OR 1.4 and 1.36; p.05) were associated weight loss
relative to SU, TZDs were negatively associated with weight loss (OR 0.86; p.05),
and GLP-1 did not differ (OR 1.55; p0.08). Patients who lost weight were 2.26 times
as likely as those who did not to attain HbA1c goal (p.05). Drug class was not
associated with HbA1c goal attainment (p0.05). CONCLUSIONS: In patients with
T2DM age 65, those who lost weight were more likely to attain HbA1C goal than
those who did not. MET and DPP-4 were associated with weight loss vs. SU, but drug
class was not associated with HbA1C goal attainment. These findings support
guideline recommendations to consider weight-effect properties of antidiabetics
in treating T2DM with data specific to patients age 65.
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OBJECTIVES: This post hoc analysis analyzed the number of patients needed to be
treated (NNT) with the GLP-1 receptor agonist exenatide once weekly (ExQW) vs
titrated insulin glargine (IG) over 26 weeks to allow one additional patient to
achieve single or combined recommended treatment goals. METHODS: Data from
the DURATION-3 trial was analyzed retrospectively. Treatment targets included: 1)
glycaemia (HbA1c 6.5% or fasting plasma glucose (FPG) 7 mmol/L); 2) systolic
blood pressure (SBP130 mmHg); 3) low-density lipoprotein cholesterol (LDL2.59
mmol/L); and 4) weight loss or maintenance. Hypoglycemic events were also as-
sessed. NNT was calculated for the entire intent-to-treat (ITT) population (ExQW
n233, IG n223) and for subpopulations of patients on different background ther-
apies (metformin  sulfonylurea). NNT was calculated using 1/Absolute Risk Re-
duction (percent of patients reaching goal in the ExQW treatment arm - percent of
patients reaching goal in the IG treatment arm). RESULTS: Baseline mean charac-
teristics were similar for both treatment groups: 45-48% women, age 58 years,
HbA1c 8.3%, and body mass index 32 kg/m2. Regardless of background therapy, 8
patients would need to be treated with ExQW in place of IG for 26 weeks to allow
one additional patient to attain the HbA1C goal. Five patients (ITT) would need to be
treated with ExQW vs IG to allow one additional patient to attain the HbA1c goal
with weight control and the absence of hypoglycaemia. Furthermore, 14 patients
(ITT) would need to be treated with ExQW versus IG to allow one additional patient
to reach combined HbA1c, SBP, and LDL goals. Only the FPG goal favored insulin use
with an NNT of -8 (ITT). Minor differences in the NNT values were observed be-
tween subpopulations for most goals. CONCLUSIONS: Both ExQW and IG treated
patients achieved therapeutic target goals. In this post hoc analysis the NNT results
favored ExQW for most goals.
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GLYCEMIC OUTCOMES AMONG PATIENTS RECEIVING EXENATIDE BID OR
LIRAGLUTIDE FOR TYPE 2 DIABETES IN CLINICAL PRACTICE: A RETROSPECTIVE
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OBJECTIVES: Exenatide twice daily (exenatide) and liraglutide once daily, GLP-1
receptor agonists, have demonstrated improvements in glycemic outcomes for
patients with type 2 diabetes (T2D) in randomized clinical trials. We evaluated A1c
outcomes for patients initiating exenatide or liraglutide in a real-world setting.
METHODS: This retrospective cohort study used data from the Medical Quality
Improvement Consortium of ambulatory medical practices that use Centricity Of-
fice from GE Healthcare IT as their electronic medical record. Patients with T2D
receiving a prescription between Jun 2005 and May 2011 were identified (ex-
enatide61,485; liraglutide9,316). Baseline A1c measures were documented from
45 days prior to 15 days after initiating exenatide or liraglutide with follow-up
measures documented at 6 months45 days. An ANCOVA model including base-
line A1c, age, gender, concomitant glucose-lowering medications, and modified
Charlson Comorbidity Index (CCI) was used to estimate least squares mean A1c.
RESULTS: Mean(SD) age was 55(12) and 55(12), CCI 2.0(1.3) and 2.1(1.3), % male 41%
and 42% for exenatide and liraglutide patients, respectively. Baseline BMI was
38.4(7.8) and 37.9(7.7) for exenatide and liraglutude patients, respectively, who had
baseline and 6 month BMI data. Of patients not at A1c goal of7.0% at baseline, the
mean(SD) baseline A1c was 8.7(1.4) for exenatide and 8.6%(1.3) for liraglutide, and
at 6 months was 8.0%(1.6) for exenatide and 7.9%(1.6) for liraglutide; 29.8% of pa-
tients receiving exenatide and 30.8% of patients receiving liraglutide achieved7%
A1c goal at 6 months. At baseline, 47% of exenatide patients were prescribed 10
mcg BID daily; 7.7% and 83.9% of liraglutide patients were prescribed 1.2 and 1.8 mg
daily, respectively. At 6 months, 66% of exenatide patients were prescribed 10 mcg
BID daily; 11.2% and 75.4% were prescribed liraglutide 1.2 and 1.8 mg daily,
respectively. CONCLUSIONS: In this retrospective cohort study, glycemic out-
comes similarly improved for patients initiating exenatide or liraglutide.
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GLARGINE UTILISATION IN RUSSIA: A PROSPECTIVE STUDY TO EVALUATE
PATIENTS SWITCHED FROM NPH INSULIN TO INSULIN GLARGINE COMPARED
WITH THOSE MAINTAINED ON NPH
Skudaev S, Verbovaya N
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OBJECTIVES: The LAntus Utilisation in RUSsia Study 2 (LAURUS 2) was an obser-
vational study undertaken at 245 sites as a follow-up to the LAURUS study. It
evaluated the efficacy of switching patients with type 2 diabetes mellitus (T2DM)
from NPH insulin to insulin glargine in real-life clinical practice.METHODS: Eligible
adult patients had taken NPH and 2 oral antidiabetes drugs (OADs) for 12 months.
During the 12-week study period all patients continued OADs. The active arm
included patients whose physicians switched their basal insulin from NPH to
glargine. Patients in the control group continued on NPH. Primary end point was
change in HbA1C. Secondary end points included changes in fasting blood glucose
(FBG) and insulin dose and hypoglycaemic episodes (HEs). RESULTS: Data were
available for 2395 of the 3000 enrolled patients. Patients had a mean duration of
diabetes of 9.3  5.1 y and mean duration of insulin therapy of 2.6  2.6 y. Mean
baseline HbA1c was 9.0  1.5 % and 9.2  1.4 % in the NPH and glargine groups,
respectively. After 12 weeks, mean HbA1c decreased by 0.6 % and 1.7 % in the NPH
and glargine groups, respectively (P 0.001). HbA1c  7% was attained by 8.4% and
25.8% of patients, respectively. Mean FBG decreased 1.4 1.7 mmol/L and 3.3 2.1
mmol/L, respectively (P 0.001). Mean insulin dose increased in both groups. At
baseline,  1 severe hypoglycaemic episode was reported by 0.4% and 0.7% of NPH
and glargine patients, respectively. At 12 weeks, no glargine patients reported se-
vere hypoglycaemia, but 2 (0.8%) NPH patients had at least 1 episode.
CONCLUSIONS: In this observational study, switching patients with T2DM who
were inadequately controlled on NPH to glargine improved glycaemic control with
minimal incidence of severe hypoglycaemia.
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A PROSPECTIVE REGISTRY TO IDENTIFY PATIENTS’ CHARACTERISTICS
ASSOCIATED WITH ACHIEVING TARGET METABOLIC CONTROL AFTER THREE
MONTHS TREATMENT WITH INSULIN GLULISINE IN TYPE 1 AND 2 DIABETES
MELLITUS PATIENTS PREVIOUSLY UNCONTROLLED ON BASAL INSULIN AND/
OR OTHER ANTI-DIABETIC TREATMENT (API REGISTRY)
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OBJECTIVES: Results from Canadian population-based studies show that glycae-
mic control (HbA1c 7.0%) is often not achieved in patients with either type 1
(T1DM) or type 2 (T2DM) diabetes mellitus. The aim of this prospective registry was
to identify patient characteristics associated with achieving HbA1c 7.0% in a
real-life setting 3 months after adding insulin glulisine to previous anti-hypergly-
caemic therapies. METHODS: The API registry included adult patients with T1DM
or T2DM who were receiving basal insulin ( anti-diabetic agents) and still had
HbA1C 7%. Patients for whom the treating physician had initiated the addition of
insulin glulisine within the month prior to study entry were assessed at baseline
and 3 months. Logistic regression using the backward elimination technique was
performed to identify the patient characteristics. RESULTS:HbA1C was available at
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baseline and 3 months in 344/383 patients who took1 dose of study drug. Patients
were obese (mean [ SD] BMI  32.3 [ 7.7] kg/m2) and 80% had T2DM. Mean
HbA1c was 9.1% ( 1.5) at baseline and 8.3% ( 1.2) after 3 months; 11.6% reached
HbA1c7%. The mealtime insulin dose at 3 months was 38.6 IU ( 28.0). A cluster of
4 factors that favourably affected glycaemic control was identified: T2DM, lower
baseline HbA1c1 hypoglycaemic event, and being Caucasian. Patients with T1DM
and those taking at least one cardiovascular medication were less likely to reach
target. Comparing the overall p-values for the crude and adjusted odds ratios sug-
gested that HbA1c at baseline, type of diabetes and higher number of hypoglycae-
mic events were interrelated, while racial group was independent of the other
factors. CONCLUSIONS: Patients who achieved HbA1c 7.0% 3 months after the
addition of insulin glulisine were likely to have T2DM, a lower baseline HbA1c, more
hypoglycaemic episodes and be Caucasian.
PDB14
ASSESSMENT OF THE CLINICAL AND ECONOMIC BENEFITS OF ADEQUATE
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OBJECTIVES: To assess the clinical and economic benefits associated with ade-
quate and early insulin initiation and intensification in people with T2DM.
METHODS: A systematic review was performed using published papers from Jan-
uary 2000 to August 2010 that assessed intervention, disease, study design and
outcomes. Studies were classified as initiation and intensification based on pre-
defined criteria. Individual studies from systematic reviews and meta-analysis
identified in our review were searched and included if relevant. RESULTS: We
screened 2690 articles, of which 76 (40 initiation and 36 intensification) studies
were included. Baseline HbA1c values were in all initiation studies8.5%. Endpoint
HbA1c values were reduced with insulin in all studies, with endpoint values rang-
ing from 6.6% to 9.8%. Similar baseline and endpoint HbA1c were seen with the
intensification studies (endpoint HbA1c ranging from 6.4% to 9.6%). Addition of
insulin to oral anti-diabetic agents (OADs) resulted in better glycaemic control in
most studies. Blood glucose levels reduced substantially with OADsinsulin com-
pared to OADs alone. Quality of life outcomes and treatment satisfaction were
reported in six studies and not significantly different for insulin versus OADs.
Hypoglycaemic events were lower with insulin initiation versus OADs (1.391.16
vs. 2.301.87; 9/27 vs. 17/28). However, all insulin types were associated with
weight gain though the comparison with OADs elicited varying results. Economic
outcomes were reported in four studies with insulin initiation. Some studies reported
a reduced incidence in diabetes-related complications with insulin, resulting in lower
diabetes-related medical and total healthcare costs in these patients. Two studies
showed that initiating insulin in those failing OADs resulted in increase in life expec-
tancy and quality-adjusted life expectancy. CONCLUSIONS: Proactive management
of uncontrolled glycaemia in people with T2DM should be considered with early
insulin initiation and intensification. Further studies are required to explore the
economic benefits with early insulin initiation and intensification.
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USE OF HYPOGLICEMIC DRUGS IN SERBIA: PHARMACOTHERAPEUTIC VERSUS
PHARMACOECONOMIC ASPECTS
Sabo A, Tomic Z
Medical faculty Novi Sad Serbia, Novi Sad, Serbia and Montenegro
OBJECTIVES: To analyse the use of hypoglycemic drugs in Serbia from pharmaco-
therapeutic and pharmacoeconomic point. To see the influence of pharmacother-
apeutic guidelines and cost on use of hipoglicemic drugs when compared with the
countries with developed pharmacotherapy. METHODS: Use of hypoglicemic
drugs in Serbia was obtained from National Agency for drugs in Serbia (ALIMS). The
costs of hypoglycemic drugs was obtained from Serbian reimbursment company.
The use of drugs was expressed in DDD/1000 inh/day, and compared to the price of
drugs in the cathegory. RESULTS: The total use of hypoglycemic drugs in Serbia (56
DDD/1000inh/day) was similar to the use of drugs in this cathegory in another
countries. Use of insulins was lower in Serbia, probably because slightly different
pharmacotherapeutic approach to DM Typ II in Serbia. The structure of oral hypo-
glycemics was similar in Serbia and in comparator countries (Norway, Finland).
While metformin was the most often used hypoglicemic drug in countries with
developed pharmacotherapy, in Serbia the most often used drugs were sulfonyl-
urea drugs, with glibenclamide and gliclaside being in the first place. Gliclaside,
being on the second place in Serbia, is the most expensive hypoglicemic drug (price
per DDD 12.15 Serbian dinars). If gliclaside would be changed with another, less
expensive drug, the national reimbursment company would spare significant
amount of money. Glimepiride, the most often used and the cheaper sulfonylurea
derivative in countries with developed phrmacotherapy, was on the third place in
Serbia. CONCLUSIONS: The total use of hypoglycemics in Serbia is comparable to
countries with developed pharmacotherapy, indicating the satisfiing level of the
treatment of diabetes mellitus. However, the structure og hypoglycemics used is
suboptimal from pharmacotherapeutic and from pharmacoeconomic point of
wiev. Significant improvement are needed, which would improve pharmacother-
apy and pharmacoeconomic aspect of use of this drugs.
PDB16
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OBJECTIVES: To assess the characteristics of type 2 diabetes patients treated with
vildagliptin (a new DPP-4 inhibitor) and to evaluate potential misuse, treatment
adherence, effectiveness and tolerability of vildagliptin under real-life conditions
of care in France.METHODS: Following a request by the French Health Technology
Agency (Haute Autorité de Santé) an observational cohort study was started in
2010. The study population included a representative sample of patients with type
2 diabetes initiating a treatment with vildagliptin. Patients were enrolled through a
national sample of vildagliptin prescribers Data collected included sociodemo-
graphic characteristics, clinical history, comorbidities, detailed treatment and lab-
oratory data, physical exam and adherence. RESULTS: Overall, 482 GPs and 84
endocrinologists enrolled 1702 patients. Sixty percent were males, mean age was
63 (11) years, mean disease duration was 7 (6.5) years and mean HbA1C 7.8%
(1.2). Forty-five percent were obese and 39% overweight, 70% were treated for
hypertension and 66% for dyslipidaemia, and 1256 patients (74%) were treated with
vildagliptin/metformin fixed combination (Eucreas, FC) and 442 (26%) with vilda-
gliptin (Galvus). Main reasons for initiating vildagliptin were: previous treatment
failure (82%), weight gain (17%), reducing the numbers of pills (16%) and intolerance
to a previous treatment (12%). In accordance to the precautions of use, 1366 pa-
tients (80%) underwent liver function tests, and 1552 patients (91%) blood creati-
nine measurement prior to treatment initiation. In few cases, vildagliptin was
prescribed to patients for whom the product was not recommended: at baseline,
2.1% of treated patients presented elevations in alanine/aspartate aminotransfer-
ase  3 times the upper limit of normal, 0.3% a NYHA class III congestive heart
failure (no class IV) and 9.3% did not respect the precautions of use for renal
function. CONCLUSIONS: Most prescriptions of vildagliptin were in accordance
with the summary of product characteristics in this large, randomly selected
French population.
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OFF-LABEL AND NON-LICENSED ENDOCRINOLOGY MEDICINE USE IN TURKEY:
A RETROSPECTIVE ANALYSIS OF COMPUTER RECORDS IN THE TURKISH
MINISTRY OF HEALTH
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OBJECTIVES: Off-label is defined by the Turkish Ministry of Health (MoHT) as the
use of licensed pharmaceutical products in doses outside of or exceeding the scope
of the registered indication, and the use of non-licensed but imported medicinal
products for the purpose of individual treatment. The use of off-label or non-
licensed endocrinology medicines were evaluated in order to provide an under-
standing of Turkey’s perspective within this area of healthcare provisions.
METHODS: A computer search was performed of IEGM’s database. A patient base
using off-label endocrinology medicine applications from 19 June 2009 to 19 June
2010 were searched. RESULTS: The computer search for the showed that 357 ap-
plications were submitted for off-label endocrinology medicine use. It was con-
cluded that the highest application percentage was established by “osteoporosis”
in all of the applications (43%, 155/357). The highest application was established by
Ankara province (28%, 44/155). University hospitals had the highest off-label osteo-
porosis medicine use applications within the given timeline (65%, 102/155). Spe-
cialized physicians in the fields of endocrinology and metabolism (adult and pae-
diatric) had the highest number of off-label osteoporosis applications (71%, 111/
155). It was concluded that the highest application percentage was established by
“teriparatide use in osteoporosis” (87%, 136/155) in all of the osteoporosis applica-
tions. 92 of 136 applications were approved. There was a significiant difference
between the T score (L1-4) of rejected and approved applications for patients
(3.071,85 and 3.231.63, respectively) (p0.001). Yet there was not a significiant
difference between ages of patients for whom applications were rejected or
approved. CONCLUSIONS: It could be said that off-label use can lead to reimburse-
ment restrictions in endocrinology, especially for teriparatide-like oncology med-
icines. In Turkey, physicians who want to prescribe an off-label or non-licensed
pharmaceutical or a medicine which has a different use from reimbursement in-
dications, need to apply through the off-label medicine use process.
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AUSTRALIA: MANAGEMENT OF THE DIABETIC FOOT WITH PEDIMED® UNDER
REAL USE CONDITIONS
Taieb C, Auges M
PFSA, Boulogne Billancourt, France
OBJECTIVES: Xerosis is a common disorder among diabetic patients; 82.1% of dia-
betic patients suffer from xerosis, which may or may not be combined with fissures
or cracking. It causes disorders which play a major role in the onset of ulceration.
Xerosis exacerbates the development and the recurrence, in particular, of hyper-
keratosis. To evaluate, under real use conditions, the effect of Pedimed (Glycerine,
petroleum jelly, piroctone olamine, tocopheryl nicotinate, hydroalcoholic ruscus
extr) on diabetic foot. METHODS: Observation study of diabetic patients with high
risk factor for foot ulceration in Australian centres, with data collected via ques-
tionnaires from patients receiving PediMed® to measure acceptability and xerosis
assessment from physicians and healthcare professionals. RESULTS: Mean age of
subjects is 57 years ( 13.3), 64% presenting with type 2 diabetes. The XAS score
measured by the doctor at inclusion is 6.4 ( 2.4) and 6.3 ( 2.6), respectively for the
right and left foot. At 4 weeks, measured by the same doctor, the XAS score is 2.7 (
2.3) and 3.0 ( 2.3) respectively for the right and left foot. Improvements are statis-
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